Beijing University of Chinese Medicine.
Department of Dermatology and Venereology, China-Japan Friendship Hospital.
Medicine (Baltimore). 2021 Feb 12;100(6):e24549. doi: 10.1097/MD.0000000000024549.
Psoriasis (PSO) is a systemic inflammatory disorder that presents with erythematous scaling of the skin and is associated with autoimmune dysfunction. Atherosclerosis is one of the major comorbidities of PSO. PSO-associated inflammatory factor IL-17 could lead to vascular endothelial cell injury and atherosclerosis. While some research results show that IL-17 helps stabilize plaque formation. Efficacy and safety on PSO and psoriatic arthritis (PSA) of existing IL-17/IL-17R biologics (secukinumab, ixekizumab, brodalumab, and bimekizumab) have been clinically validated, but whether they can improve atherosclerotic outcomes in psoriatic patients remains controversial.
Seven electronic search engines will be searched from inception to December 1, 2020, including PubMed, Embase, Scopus, PsycINFO, Global Health, Web of Science and the Cochrane Library. Clinical trial registries, potential grey literature, relevant conference abstracts, and reference lists of identified studies will also be searched. Literature selection, data extraction, and quality assessment will be done by 2 independent authors. Based on the heterogeneity test, the fixed effect or random effect model will be used for data synthesis. Changes in lung function will be evaluated as the primary outcome. Assessment of symptoms, quality of life, medication use, exacerbations and adverse events will be assessed as secondary outcomes. RevMan V. 5.3.5 (The Nordic Cochrane Centre, Copenhagen, Denmark) will be used for meta-analysis.
This study will provide a synthesis of current evidence of IL-17/IL-17R inhibitors on atherosclerosis in PSO and PSA.
The conclusion of our study will provide updated evidence to judge whether IL-17/IL-17R inhibitors is an effective solution to atherosclerosis as comorbidity of PSO and PSA.
CRD42020209897.
银屑病（PSO）是一种全身性炎症性疾病，表现为皮肤红斑和鳞屑，并伴有自身免疫功能障碍。动脉粥样硬化是 PSO 的主要合并症之一。PSO 相关炎症因子 IL-17 可导致血管内皮细胞损伤和动脉粥样硬化。虽然一些研究结果表明，IL-17 有助于稳定斑块形成，但现有的 IL-17/IL-17R 生物制剂（司库奇尤单抗、依奇珠单抗、布罗达单抗和倍美克珠单抗）对 PSO 和银屑病关节炎（PSA）的疗效和安全性已在临床上得到验证，但它们是否能改善银屑病患者的动脉粥样硬化结局仍存在争议。
从建库到 2020 年 12 月 1 日，我们将检索 7 个电子数据库，包括 PubMed、Embase、Scopus、PsycINFO、全球健康、Web of Science 和 Cochrane 图书馆。同时，还将检索临床试验注册库、潜在灰色文献、相关会议摘要以及确定研究的参考文献。文献选择、数据提取和质量评估将由 2 名独立作者完成。根据异质性检验，将使用固定效应或随机效应模型进行数据合并。肺功能变化将作为主要结局进行评估。症状、生活质量、药物使用、恶化和不良反应的评估将作为次要结局。Meta 分析将使用 RevMan V.5.3.5（丹麦哥本哈根 Nordic Cochrane 中心）进行。
本研究将综合目前关于 IL-17/IL-17R 抑制剂对 PSO 和 PSA 患者动脉粥样硬化的证据。
我们的研究结论将提供更新的证据，以判断 IL-17/IL-17R 抑制剂是否是 PSO 和 PSA 合并症的动脉粥样硬化的有效治疗方法。
PROSPERO 注册号：CRD42020209897。
